Back to top

Galmed announces development of novel LNP cardiac targeted Aramchol formulation

Galmed (GLMD) announced the breakthrough development of a new Aramchol-based lipid nanoparticles formulation, or LNP, for targeted delivery to the ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Galmed Pharmaceuticals Ltd. (GLMD)